Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cabozantinib in High Grade Neuroendocrine Neoplasms

NCT04412629 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04412629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04412629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cabozantinib in High Grade Neuroendocrine Neoplasms
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 24, 2020
Completion date
March 31, 2027
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high grade neuroendocrine neoplasms